9 Meters Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	0	0	0	0	0	0	4.07	8.27	11.34
Revenue Growth (YoY)	-	-	-	-	-	-	-50.82%	-27.13%	-
Cost of Revenue	0	0	0	0	0	0	3.33	7.84	11.11
Gross Profit	0	0	0	0	0	0	0.74	0.43	0.23
Selling, General & Admin	11.01	9.66	10.52	10.57	10.66	7.16	6.41	6.55	6.37
Research & Development	31.01	22	10.93	13.72	7.56	4.01	0.27	0.33	0.54
Other Operating Expenses	0	5.1	32.27	0	0	0	0	0	0
Operating Expenses	42.02	36.76	53.72	24.28	18.22	11.17	6.68	6.89	6.91
Operating Income	-42.02	-36.76	-53.72	-24.28	-18.22	-11.17	-5.94	-6.46	-6.68
Interest Expense / Income	2.67	0.05	4.05	1.83	6.15	0.44	0.83	1.38	1.66
Other Expense / Income	-0.92	-0.03	3.73	0.94	-0.21	-	-0.56	0.9	2.71
Pretax Income	-43.77	-36.78	-61.5	-27.05	-24.16	-11.61	-6.21	-8.74	-11.04
Income Tax	0	0	0	0	0	0	0	0	0.01
Net Income	-43.77	-36.78	-61.5	-27.05	-24.16	-11.61	-6.21	-8.74	-11.06
Shares Outstanding (Basic)	13	12	5	2	1	1	0	0	0
Shares Outstanding (Diluted)	13	12	5	2	1	1	0	0	0
Shares Change	6.58%	130.12%	216.97%	34.59%	108.29%	2053.67%	67.58%	17.62%	-
EPS (Basic)	-3.38	-3.03	-11.60	-16.20	-19.60	-19.60	-225.20	-530.00	-790.00
EPS (Diluted)	-3.38	-3.03	-11.60	-16.20	-19.60	-19.60	-225.20	-530.00	-790.00
Free Cash Flow	-37.25	-29.49	-19.41	-17.98	-15.18	-5.14	-8.43	-1.73	-7.45
Free Cash Flow Per Share	-2.88	-2.43	-3.67	-10.79	-12.26	-8.64	-305.33	-105.04	-532.17
Gross Margin	-	-	-	-	-	-	18.11%	5.15%	2.06%
Operating Margin	-	-	-	-	-	-	-146.20%	-78.15%	-58.86%
Profit Margin	-	-	-	-	-	-	-152.84%	-105.75%	-97.48%
Free Cash Flow Margin	-	-	-	-	-	-	-207.31%	-20.93%	-65.70%
EBITDA	-41.09	-36.72	-57.43	-25.2	-17.99	-11.16	-5.39	-7.36	-9.38
EBITDA Margin	-	-	-	-	-	-	-132.50%	-89.02%	-82.72%
Depreciation & Amortization	0.01	0.01	0.02	0.02	0.02	0.01	0	0	0
EBIT	-41.1	-36.73	-57.45	-25.22	-18.01	-11.17	-5.39	-7.36	-9.38
EBIT Margin	-	-	-	-	-	-	-132.50%	-89.02%	-82.72%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).